High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020-March 2021.

Autor: Iwamoto C; Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329, USA., Lesteberg KE; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Lamb MM; Department of Epidemiology and Center for Global Health, Colorado School of Public Health, 13199 E. Montview Blvd, Aurora, CO 80045, USA., Calvimontes DM; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala.; La Comisión Presidencial de Atención a la Emergencia COVID-19 (Coprecovid), Guatemala City 01010, Guatemala., Guo K; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Barrett BS; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Mickens KL; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Duca LM; Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329, USA., Monzon J; Centers for Disease Control and Prevention, Division of Global Health Protection (CDC-DGHP), 1600 Clifton Rd., Atlanta, GA 30329, USA., Chard AN; Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329, USA., Guzman G; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Barrios E; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Rojop N; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Arias K; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Gomez M; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Paiz C; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Bolanos GA; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala., Edwards KM; Division of Infectious Disease, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 Children's Way, 6th Floor, Nashville, TN 37232, USA., Zielinski Gutierrez E; Centers for Disease Control and Prevention, Division of Global Health Protection (CDC-DGHP), 1600 Clifton Rd., Atlanta, GA 30329, USA., Azziz-Baumgartner E; Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30329, USA., Asturias EJ; Department of Epidemiology and Center for Global Health, Colorado School of Public Health, 13199 E. Montview Blvd, Aurora, CO 80045, USA.; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala.; La Comisión Presidencial de Atención a la Emergencia COVID-19 (Coprecovid), Guatemala City 01010, Guatemala.; Division of Infectious Disease, Department of Pediatrics, University of Colorado School of Medicine, 13123 E. 16th Ave., Aurora, CO 80045, USA., Santiago ML; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Beckham JD; Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, 13001 E. 17th Pl, Aurora, CO 80045, USA., Olson D; Department of Epidemiology and Center for Global Health, Colorado School of Public Health, 13199 E. Montview Blvd, Aurora, CO 80045, USA.; Center for Human Development, Fundación para la Salud Integral de los Guatemaltecos, FSIG, Km 30 carretera de Coatepeque a Chiquirines Caballo Blanco, Retalhuleu 11010, Guatemala.; Division of Infectious Disease, Department of Pediatrics, University of Colorado School of Medicine, 13123 E. 16th Ave., Aurora, CO 80045, USA.
Jazyk: angličtina
Zdroj: Vaccines [Vaccines (Basel)] 2022 Jul 21; Vol. 10 (7). Date of Electronic Publication: 2022 Jul 21.
DOI: 10.3390/vaccines10071160
Abstrakt: Essential agricultural workers work under occupational conditions that may increase the risk of SARS-CoV-2 exposure and transmission. Data from an agricultural worker cohort in Guatemala, and anti-SARS-CoV-2 nucleocapsid IgG (anti-N IgG) testing were used to estimate past infections and analyze risk factors associated with seropositivity at enrollment and association with SARS-CoV-2 infection. The stability of neutralizing antibody (NAb) responses were assessed in a subset of participants. The adjusted relative risk (aRR) for seroprevalence at enrollment was estimated accounting for correlations within worksites. At enrollment, 616 (46.2%) of 1334 (93.2%) participants had anti-N IgG results indicating prior SARS-CoV-2 infection. A cough ≤ 10 days prior to enrollment (aRR = 1.28, 95% CI: 1.13−1.46) and working as a packer (aRR = 2.00, 95% CI: 1.67−2.38) or packing manager within the plants (aRR = 1.82, 95% CI: 1.36−2.43) were associated with increased risk of seropositivity. COVID-19 incidence density among seronegative workers was 2.3/100 Person-Years (P-Y), higher than seropositive workers (0.4/100 P-Y). Most workers with follow-up NAb testing (65/77, 84%) exhibited a 95% average decrease in NAb titers in <6 months. While participants seropositive at baseline were less likely to experience a symptomatic SARS-CoV-2 infection during follow-up, NAb titers rapidly waned, underscoring the need for multipronged COVID-19 prevention strategies in the workplace, including vaccination.
Databáze: MEDLINE
Externí odkaz: